IP Library › Granted Patent US 8,202,999
Granted Patent B2
US 8,202,999 · App. 11/326,872 · Granted Jun 19, 2012

Compounds for inflammation and immune-related uses

Assignee: Synta Pharmaceuticals Corp.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,202,999
App. No.
11/326,872
Granted
Jun 19, 2012
Kind
B2
Abstract

The invention relates to compounds of structural formulas (I), (VII) and (XI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein X 1 , X 2 , X 3 , Y, Z, L, R 1 , R 2 , R 3 , R 18 and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

Claims (45)

1. A compound represented by formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

L is —NR—C(O)—;

X 1 and X 3 are each CH;

X 2 is CH;

each Z is independently selected from the group consisting of a lower alkyl, a lower haloalkyl, a halo, a lower alkoxy, a lower alkyl sulfanyl, cyano, nitro, or lower haloalkoxy;

R, for each occurrence is independently selected from —H, an alkyl, —C(O)R 5 , or —C(O)OR 5 ;

R 1 and R 2 are each, independently, a halo, a lower alkyl, a lower alkoxy, or a haloalkoxy;

R 3 is an alkyl, a haloalkyl, a halo, a haloalkoxy, —OR 5 , —SR 5 , or —NR 6 R 7 ;

R 18 is an optionally substituted pyridinyl, an optionally substituted oxazolyl, an optionally substituted isoxazolyl, an optionally substituted pyrazolyl, an optionally substituted thiazolyl, an optionally substituted pyrrolyl, an optionally substituted morpholinyl, an optionally substituted furanyl, an optionally substituted thienyl, an optionally substituted thiadiazolyl, an optionally substituted triazolyl, an optionally substituted oxadiazolyl, an optionally substituted imidazolyl, or an optionally substituted tetrazolyl;

R 5 , for each occurrence, is independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl;

R 6 and R 7 , for each occurrence are, independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl; or R 6 and R 7 taken together with the nitrogen to which they are attached are an optionally substituted heterocyclyl or optionally substituted heteroaryl; and

n is zero or an integer from 1 to 4.

2. The compound of claim 1 , wherein R 18 is unsubstituted or substituted with one or more substituents selected from the group consisting of a lower alkyl, halo, a lower haloalkyl, an amino, a lower dialkyl amino, a lower alkyl amino, a lower alkoxy, and a lower alkyl sulfanyl.

3. The compound of claim 1 , wherein n is 0.

4. The compound of claim 1 , wherein L is —NHC(O)—.

5. The compound of claim 4 , wherein the compound is represented by formula (III):

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 5 , wherein R 1 and R 2 are each, independently, a halo.

7. The compound of claim 6 , wherein R 3 is a lower alkyl, a lower alkoxy, a lower alkyl sulfanyl, a lower alkylamino, a lower dialkylamino, or a halo.

8. The compound of claim 7 , wherein R 18 is an optionally substituted pyridyl.

9. The compound of claim 7 , wherein R 1 and R 2 are each a fluoro group.

10. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of claim 1 .

11. The pharmaceutical composition of claim 10 , further comprising one or more therapeutic agents.

12. The pharmaceutical composition according to claim 11 , wherein the therapeutic agent is selected from the group consisting of immunosuppressive agents, anti-inflammatory agents and suitable mixtures thereof.

13. The pharmaceutical composition of claim 12 , wherein the therapeutic agent is selected from the group consisting of steroids, non-steroidal anti-inflammatory agents, antihistamines, analgesics, and suitable mixtures thereof.

14. A compound represented by formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

L is —NR—C(O)—;

X 1 , X 2 , and X 3 are each CH;

each Z is independently selected from the group consisting of a lower alkyl, a lower haloalkyl, a halo, a lower alkoxy, a lower alkyl sulfanyl, cyano, nitro, or lower haloalkoxy;

R, for each occurrence is independently selected from —H, an alkyl, —C(O)R 5 , or —C(O)OR 5 ;

R 1 and R 2 are each, independently, a halo, a lower alkyl, a lower alkoxy, or a haloalkoxy;

R 3 is an alkyl, a haloalkyl, a halo, a haloalkoxy, —OR 5 , —SR 5 , or —NR 6 R 7 ;

R 18 is an ester, amide or carboxylic acid bioisostere;

R 5 , for each occurrence, is independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl;

R 6 and R 7 , for each occurrence are, independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl; or R 6 and R 7 taken together with the nitrogen to which they are attached are an optionally substituted heterocyclyl or optionally substituted heteroaryl; and

n is zero or an integer from 1 to 4.

15. The compound of claim 14 , wherein R 18 is an optionally substituted oxazolyl, an optionally substituted thiazolyl, an optionally substituted 1H-tetrazolyl, an optionally substituted 1H-imidazolyl, an optionally substituted [1,2,4]oxadiazolyl, or an optionally substituted 4H-[1,2,4]triazolyl.

16. A compound represented by formula (III):

or a pharmaceutically acceptable salt thereof, wherein:

R 1 and R 2 are each, independently, a halo;

R 3 is a lower alkyl, a lower alkoxy, a lower alkyl sulfanyl, a lower alkylamino, a lower dialkylamino, or a halo; and

R 4 is a 5-membered heteroaryl.

17. The compound of claim 16 , wherein R 4 is an optionally substituted oxazolyl, an optionally substituted thiazolyl, an optionally substituted 1H-tetrazolyl, an optionally substituted 1H-imidazolyl, an optionally substituted [1,2,4]oxadiazolyl, or an optionally substituted 4H-[1,2,4]triazolyl.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2006
From: SUN, LIJUN; CHEN, SHOUJUN; XIA, ZHI-QIANG; JIANG, JUN; XIE, YU; ZHANG, JUNYI
To: SYNTA PHARMACEUTICALS CORP.
Reel/Frame 017470/0541 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2006
From: SUN, LIJUN; CHEN, SHOUJUN; XIA, ZHI-QIANG; JIANG, JUN; XIE, YU; ZHANG, JUNYI
To: SYNTA PHARMACEUTICALS CORP.
Reel/Frame 017470/0551 →
Continuity (3)
Provisional Application 60642179 · Jan 7, 2005
Provisional Application 60707845 · Aug 12, 2005
Related Publication 20060173006A1 · Aug 3, 2006